Abstract:1112 Objectives: GluN2B is the most studied subunit of N‑methyl‑D‑aspartate receptors (NMDARs), which are related to the pathologies of various central nervous system disorders and neurodegenerative diseases, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Schizophrenia and neuropathic pain [1]. However, the in vivo imaging of GluN2B subunit remains a challenge. Herein we attempt to develop novel probes for positron emission computed tomography (PET) imaging of the GluN2B subunit. Methods: The synthesis of cold compound 5, 2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide, was achieved following a 3-step process [2]. The amidation of starting material 2-bromo-acetic acid 1 with methylamine in THF solution afforded the 2-bromo-N,N-dimethylacetamide 2. A SN2 reaction between amide 2 and 6-bromo-1H-pyrrolo[3,2-b]pyridine 3 in the presence of K2CO3 in DMF gave 2-(6-bromo-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide 4 with a yield of 81%. Then Pd(dppf)Cl2-catalyzed cross-coupling between amide 4 and (4-fluoro-3-methylphenyl)boronic acid provided the title product. By following the same method, 11C-labeling precursor, 2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N-methylacetamide 8, was obtained by replacing methylamine in THF solution with H2NMe·HCl. Radiosynthesis of [11C]5 was obtianed using [11C]CH3I with K2CO3 in DMSO at 130 oC from precursor 8. The brain uptake studies were conducted in mice after 1, 2, and 5 min post-injection. Results: The cold compound 5 was obtained in total yield of 21% over 3 steps, and the corresponding precursor 8 was achieved in 18%. The biological assay of compound 5 in trifluoroacetate salt form has been reported with pIC50 = 6.3 ([3H] inhibition binding assay) [2].11C-methylation strategy delivered the tracer [11C]5 in 4% isolated radiochemical yield (non-decay corrected from [11C]CO2) with high radiochemical purity (>99%) and high specific activity of 17.7 GBq/μmol. The brain uptake study revealed that [11C]5 exhibited moderate standard uptake valves (SUVs) in mice brain with the values of 0.61, 0.55 and 0.50 at 1, 2, and 5 min post-injection, respectively. Conclusions: We have successfully synthesized and radiolabeled a potent GluN2B-selective NMDA receptor antagonist [11C]5, which showed moderate brain uptake in mice brain. Further studies including radiolabeling of the analogous, blocking studies, ex in vivo biodistribution, and dynamic PET scan are on the way. References: [1] Cur Top Med. Chem. 2016, 16, 1830-1842; [2] US2018208595, 2018.

Radiolabel uncovers nonintuitive metabolites of AMPAR potentiator BIIB104: Novel release of [ 14 C]cyanide from 2-cyanothiophene and subsequent formation of [ 14 C]thiocyanate

Synthesis of [11C]BIIB104, an α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic-Acid-Positive Allosteric Modulator, and Evaluation of the Bio-Distribution in Non-Human Primate Brains Using Positron Emission Tomography

Rational Design of a Two‐Photon Fluorescent Probe for Human Cytochrome P450 3A and the Visualization of Mechanism‐Based Inactivation

An Overview of Radio or Stable Isotope‐labeled Cis‐neonicotinoid Analogs

Highly Efficient Radiosynthesis and Biological Evaluation of [18 F]Safinamide, a Radiolabelled Anti-Parkinsonian Drug for Positron Emission Tomography Imaging.

Bioactivation of 3-N-butylphthalide Via Sulfation of Its Major Metabolite 3-Hydroxy-nbp: Mediated Mainly by Sulfotransferase 1A1

Synthesis, Radiolabeling And Biodistribution Studies Of [Tc-99m(Co)(3)(Mn-Tz-Bpa)](+) In Tumor-Bearing Mice

In Silico and Chromatographic Methods for Analysis of Biotransformation of Prospective Neuroprotective Pyrrole-Based Hydrazone in Isolated Rat Hepatocytes

Synthesis and preliminary evaluation of novel 11C-labeled GluN2B-selective NMDA receptor negative allosteric modulators

Study of the mass balance, biotransformation, and safety of [ 14C]IBI351 in healthy Chinese subjects

Metabolite Study and Structural Authentication for the First-in-Human Use Sphingosine-1-phosphate Receptor 1 Radiotracer

Radiosynthesis and Preliminary Evaluation of 11C-Labeled 4-Cyclopropyl-7-(3-methoxyphenoxy)-3,4-dihydro-2h-benzo[e] [1,2,4] Thiadiazine 1,1-Dioxide for PET Imaging AMPA Receptors.

Synthesis, radiolabeling and biodistribution studies of [ 99m Tc(CO) 3 (MN-TZ-BPA)] + in tumor-bearing mice

Elucidating the structure and cytochrome P450-mediated mechanism for novel metabolites of GDC-0575 in rats

Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for β-amyloid plaques in Alzheimer’s disease

Synthesis and preclinical evaluation of <SUP>11</SUP>C-labeled (6-aryl-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)acetamide for imaging GluN2B subunit of NMDA receptors

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

Synthesis and Preliminary Biological Evaluation of 99m Tc(CO) 3 -Labeled Pegylated 2-Nitroimidazoles

Metabolic characterization of the new benzimidazole synthetic opioids - nitazenes

An Improved Radiosynthesis of [18F]AV-133: a PET Imaging Agent for Vesicular Monoamine Transporter 2.

In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)